It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The development of the striatum dopamine (DA) system through human adolescence, a time of increased sensation seeking and vulnerability to the emergence of psychopathology, has been difficult to study due to pediatric restrictions on direct in vivo assessments of DA. Here, we applied neuroimaging in a longitudinal sample of n = 146 participants aged 12–30. R2′, an MR measure of tissue iron which co-localizes with DA vesicles and is necessary for DA synthesis, was assessed across the sample. In the 18–30 year-olds (n = 79) we also performed PET using [11C]dihydrotetrabenazine (DTBZ), a measure of presynaptic vesicular DA storage, and [11C]raclopride (RAC), an indicator of D2/D3 receptor availability. We observed decreases in D2/D3 receptor availability with age, while presynaptic vesicular DA storage (as measured by DTBZ), which was significantly associated with R2′ (standardized coefficient = 0.29, 95% CI = [0.11, 0.48]), was developmentally stable by age 18. Our results provide new evidence for maturational specialization of the striatal DA system through adolescence.
How the human dopamine system changes during adolescence is still unclear. Here, the authors combine PET and quantitative MRI measures to show that dopamine D2/D3 receptor availability decreases with age while presynaptic dopamine vesicular storage was developmentally stable by age 18
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 University of Pittsburgh, Department of Psychiatry, Pittsburgh, USA (GRID:grid.21925.3d) (ISNI:0000 0004 1936 9000)
2 NUBIC, Northeastern University, Boston, USA (GRID:grid.261112.7) (ISNI:0000 0001 2173 3359)
3 University of Pittsburgh, Department of Psychiatry, Pittsburgh, USA (GRID:grid.21925.3d) (ISNI:0000 0004 1936 9000); University of Pittsburgh, Department of Bioengineering, Pittsburgh, USA (GRID:grid.21925.3d) (ISNI:0000 0004 1936 9000)
4 University of Pittsburgh, Department of Bioengineering, Pittsburgh, USA (GRID:grid.21925.3d) (ISNI:0000 0004 1936 9000); University of Pittsburgh, Department of Radiology, Pittsburgh, USA (GRID:grid.21925.3d) (ISNI:0000 0004 1936 9000)
5 University of Pittsburgh, Department of Radiology, Pittsburgh, USA (GRID:grid.21925.3d) (ISNI:0000 0004 1936 9000)
6 Massachusetts General Hospital, Harvard Medical School, Charlestown, USA (GRID:grid.21925.3d)